{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:31:19Z","timestamp":1789486279008,"version":"build-2803163510"},"reference-count":12,"publisher":"Walter de Gruyter GmbH","issue":"9","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n Albuminuria is a key biomarker of kidney damage, yet preanalytical challenges with conventional liquid urine testing, limiting its utility for decentralized and large-scale screening. This study evaluated the analytical performance of a novel dried urine spot (DUS) device, for measuring urinary albumin-to-creatinine ratio and assessed its agreement with standard liquid urine analysis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n One hundred routine urine samples were analysed both as liquid and dried specimens prepared with the DUS device. After drying, discs were eluted and tested on three clinical chemistry platforms (Roche Cobas Pro, Abbott Alinity, Siemens Atellica). Albumin-to-creatinine ratio (ACR) was calculated. Statistical analyses included duplicate precision (coefficient of variation), linear regression, and Bland-Altman comparison. A stability study was conducted under multiple temperature conditions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n ACR values obtained from DUS samples showed strong concordance with liquid urine results (Roche Cobas Pro: y=1.024\u00d7\u20131.427; R\n 2<\/jats:sup>\n =0.997; Siemens Atellica y=0.983\u00a0+\u00a00.336; R\n 2<\/jats:sup>\n =0.958 and Abbott Alinity: y=1.062\u00d7\u20130.360; R\n 2<\/jats:sup>\n =0.991). Across ACR intervals (<3\u202fmg\/mmol, 3\u201330\u202fmg\/mmol >30\u202fmg\/mmol), Cobas demonstrated small positive median differences (0.46, 0.25, 0.62\u202fmg\/mmol), Alinity showed variable differences (\u22120.87, 0.27,\u00a0\u22120.24\u202fmg\/mmol), and Atellica yielded consistently positive, slightly larger differences (0.47, 2.42, 1.33\u202fmg\/mmol).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The DUS device provides a robust and reproducible alternative to liquid urine sampling for albumin\u00a0and creatinine measurement. Its ability to enable decentralized, ambient-temperature collection with strong analytical agreement supports its application in population screening, remote monitoring, and kidney disease research.<\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/cclm-2026-0034","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:56:01Z","timestamp":1782730561000},"page":"2045-2054","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of albumin-to-creatinine ratio on automated analysers using a microsampling card (Capitainer DIP70 card) for the collection of urine"],"prefix":"10.1515","volume":"64","author":[{"given":"Johan","family":"Olausson","sequence":"first","affiliation":[{"name":"Department of Medical Sciences , Uppsala University , Uppsala , Sweden"},{"name":"Capitainer , Solna , Sweden"},{"name":"Department of Clinical Chemistry , \u00d6stersund\u2019s Hospital , \u00d6stersund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences , Uppsala University , Uppsala , Sweden"},{"name":"Capitainer , Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Poland","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry , RHMDC , Delft , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"van Loosdregt","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry , Elkerliek Hospital , Helmond , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-0402","authenticated-orcid":false,"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences , Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2026091512595708666_j_cclm-2026-0034_ref_001","doi-asserted-by":"crossref","unstructured":"Claudel, SE, Verma, A. Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review. Circulation 2025;151:123\u2013e135. https:\/\/doi.org\/10.1161\/circulationaha.124.071079.","DOI":"10.1161\/CIRCULATIONAHA.124.071079"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_002","doi-asserted-by":"crossref","unstructured":"Beernink, JM, Heerspink, HJL. Developments in albuminuria testing: a key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease. Diabetes Obes Metab 2025;27:e16359.","DOI":"10.1111\/dom.16359"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_003","doi-asserted-by":"crossref","unstructured":"Shin, JI, Chang, AR, Grams, ME, Coresh, J, Ballew, SH, Surapaneni, A, et al.. Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis. Hypertension 2021;78:1042\u201352. https:\/\/doi.org\/10.1161\/hypertensionaha.121.17323.","DOI":"10.1161\/HYPERTENSIONAHA.121.17323"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_004","doi-asserted-by":"crossref","unstructured":"Seegmiller, JC, Bachmann, LM. Urine albumin measurements in clinical diagnostics. Clin Chem 2024;70:382\u201391. https:\/\/doi.org\/10.1093\/clinchem\/hvad174.","DOI":"10.1093\/clinchem\/hvad174"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_005","doi-asserted-by":"crossref","unstructured":"Dikmen, ZG, Pinar, A, Akbiyik, F. Specimen rejection in laboratory medicine: necessary for patient safety? Biochem Med 2015;25:377\u201385. https:\/\/doi.org\/10.11613\/bm.2015.037.","DOI":"10.11613\/BM.2015.037"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_006","doi-asserted-by":"crossref","unstructured":"LaRocco, MT, Franek, J, Leibach, EK, Weissfeld, AS, Kraft, CS, Sautter, RL, et al.. Effectiveness of preanalytic practices on contamination and diagnostic accuracy of urine cultures: a laboratory medicine best practices systematic review and meta-analysis. Clin Microbiol Rev 2016;29:105\u201347. https:\/\/doi.org\/10.1128\/cmr.00030-s15.","DOI":"10.1128\/CMR.00030-15"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_007","doi-asserted-by":"crossref","unstructured":"Suwanvecho, C, Vyle\u0165alov\u00e1, L, P\u0159\u00edvratsk\u00e1, N, Laolertworakul, P, Turo\u0148ov\u00e1, D, Vo\u0161mik, M, et al.. Dried urine spot as a stable, green, and practical microsampling tool in clinical practice for quantification of neopterin and creatinine. Green Chem 2025;27:11007\u201320. https:\/\/doi.org\/10.1039\/d5gc00956a.","DOI":"10.1039\/D5GC00956A"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_008","doi-asserted-by":"crossref","unstructured":"L\u00f6fgren, L, von Euler Chelpin, M, Bhat, M, Althage, M, Hober, A, Edfors, F, et al.. Patient-centric quantitative microsampling for accurate determination of urine albumin to creatinine ratio (UACR) in a clinical setting. J\u00a0Appl Lab Med 2024;9:329\u2013419. https:\/\/doi.org\/10.1093\/jalm\/jfad111.","DOI":"10.1093\/jalm\/jfad111"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_009","doi-asserted-by":"crossref","unstructured":"Kiseleva, OI, Ikhalaynen, YA, Kurbatov, IY, Arzumanian, VA, Kryukova, PA, Poverennaya, EV. Dried spot paradigm: problems and prospects in proteomics. Int J Mol Sci 2025;26:3857. https:\/\/doi.org\/10.3390\/ijms26083857.","DOI":"10.3390\/ijms26083857"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_010","doi-asserted-by":"crossref","unstructured":"Protti, M, Sberna, PM, Sberna, AE, Ferrante, R, Mandrioli, R, Mercolini, L. Enhanced urinary stability of peptide hormones and growth factors by dried urine microsampling. J\u00a0Pharm Biomed Anal 2021;204:114234. https:\/\/doi.org\/10.1016\/j.jpba.2021.114234.","DOI":"10.1016\/j.jpba.2021.114234"},{"key":"2026091512595708666_j_cclm-2026-0034_ref_011","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Evaluation of stability of in\u00a0vitro medical laboratory test reagents; CLSI guideline EP25, 1st ed. Wayne, PA: CLSI; 2023."},{"key":"2026091512595708666_j_cclm-2026-0034_ref_012","doi-asserted-by":"crossref","unstructured":"KDIGO CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2024;105:S117\u2013314.","DOI":"10.1016\/j.kint.2023.09.002"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0034\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:04:24Z","timestamp":1789477464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2026-0034\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":12,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,8,24]]}},"alternative-id":["10.1515\/cclm-2026-0034"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2026-0034","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}